Cancer Diagnosis and Treatment
Open access
Peer reviewed
Scollr summary
What this paper is about
Nivolumab was tolerated in patients with CUP in routine practice in Japan, with no new safety concerns, and indicated antitumor activity consistent with clinical trial results.
Full abstract
Read the full abstract
BACKGROUND: Cancer of unknown primary (CUP) is associated with poor prognosis. In December 2021, nivolumab was approved in Japan for the treatment of CUP based on a small phase II trial. This post-marketing surveillance (PMS) evaluated the real-world safety and effectiveness of nivolumab in Japanese patients with CUP. METHODS: This prospective, observational, PMS enrolled patients with CUP who initiated nivolumab between April 2022 and June 2023 at 66 institutions. Patients were observed for 6 months. Safety outcomes were treatment-related adverse events (TRAEs), and effectiveness outcomes included overall response rate (ORR) and overall survival (OS). Analyses were descriptive. RESULTS: Among 151 patients in the safety set, the median age was 70 years and 79.5% had an Eastern Cooperative Oncology Group performance status (PS) 0-1. Any grade and Grade ≥ 3 TRAEs occurred in 25.2% and 11.9% of patients, respectively. Frequently reported TRAEs included interstitial lung disease (3.3%), hepatic function abnormal (2.6%), and hypothyroidism (2.6%). There was one TRAE (neutropenia) resulting in death. In the effectiveness set (n = 144), the ORR was 21.5%. ORR was higher in patients without prior systemic therapy (25.4% vs. 18.2%) and in those with lymph node-only involvement (36.6% vs. 15.5%). The 6-month OS rate was 71.0%, and median OS was not reached. The 6-month OS rates were greater in patients with PS 0-1 and lymph node-only involvement. CONCLUSIONS: Nivolumab was tolerated in patients with CUP in routine practice in Japan, with no new safety concerns, and indicated antitumor activity consistent with clinical trial results. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT2041240121).
Direct answer
What can I do from this paper page?
Use this page to scan "Real-world safety and effectiveness of nivolumab in patients with cancer of unknown primary: results from a nationwide post-marketing surveillance in Japan" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Cancer Diagnosis and Treatment research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Kawasaki2026Real,
title = {Real-world safety and effectiveness of nivolumab in patients with cancer of unknown primary: results from a nationwide post-marketing surveillance in Japan},
author = {Akira Kawasaki and Akito Kakuuchi and Ayumi Akamatsu and Misato Nakanishi and Chikara Honda},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03147-3},
url = {https://doi.org/10.1007/s10147-026-03147-3}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Cancer Diagnosis and Treatment research papers?
Follow Cancer Diagnosis and Treatment research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Real-world safety and effectiveness of nivolumab in patients with cancer of unknown primary: results from a nationwide post-marketing surveillance in Japan. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app